Entrada Therapeutics is a clinical-stage biopharmaceutical company pioneering a novel approach to treating devastating diseases. We develop Endosomal Escape Vehicle (EEV™) therapeutics, designed for efficient intracellular delivery of proteins, peptides, and nucleic acids, overcoming limitations of traditional large and small molecule therapies. This innovative technology allows us to target previously inaccessible intracellular pathways, advancing a robust portfolio of RNA-, antibody-, and enzyme-based programs for neuromuscular, ocular, metabolic, and immunological diseases. Our lead oligonucleotide programs are in development for Duchenne muscular dystrophy, and we've partnered on a clinical-stage program for myotonic dystrophy type 1. Entrada operates with a strong tech foundation, utilizing technologies such as Drupal 10, Akamai EdgeWorkers, and BunnyCDN Header for our web infrastructure and various other technologies for streamlining internal processes. Our engineering culture fosters collaboration and innovation, valuing a balance between cutting-edge technology and patient-focused results. We pride ourselves on our values of Humanity, Tenacity, Creativity, Collaboration, and Curiosity – these principles guide our work and interactions. We're a dynamic team of experts in therapeutic development and rare diseases, currently employing 101-250 people and headquartered in Boston, MA. With significant funding secured and a growing pipeline of promising therapies, Entrada is poised for continued growth and expansion. We offer a variety of remote work opportunities and employee benefits designed to support a positive work-life balance. Entrada is an equal opportunity employer committed to fostering a diverse and inclusive workplace. We encourage candidates from all backgrounds to apply.
Ascend Advanced Therapies partners with life science innovators to bring cutting-edge gene therapy products to patients. We offer unparalleled collaboration, guiding your products from the bench through clinical trials and beyond. Our expertise spans gene therapy development and commercialization, leveraging a world-class analytical toolkit within our scalable AAV platform. We prioritize scientific innovation, quality, and responsibility, constantly striving to improve yield and quality in each process. Ascend operates in a dynamic and competitive market, positioning itself as a leader in gene therapy manufacturing. Our unique IP and platform assets give us a competitive edge, while our team of industry veterans—a result of recent acquisitions of Freeline Therapeutics and Beacon Therapeutics teams—brings decades of experience. We offer a collaborative and forward-thinking environment, embracing adaptability and continuous improvement. We are committed to serving patients by serving our partners, fostering a culture of mutual trust and support. Our tech stack includes Amazon web services and CRM software (HubSpot mentioned). We utilize various analytical tools (including, but not limited to, Global Data and Zymewire), and our employees benefit from opportunities for professional development and advancement. With over 120 employees across multiple locations, including Alachua, FL and Rockville, MD, we are rapidly expanding and shaping the future of accessible life-saving therapies. Ascend is a privately held company, recently securing significant funding. Our growth trajectory is robust, driven by a strong pipeline of promising gene therapy projects and a commitment to innovation and excellence.
Helix is a company involved in the healthcare and technology sectors, focusing on innovative solutions and products, as suggested by its job openings in sales and clinical informatics.
SAGA Diagnostics is a personalized cancer medicine company specializing in molecular genetic analyses of circulating tumor DNA (ctDNA) and tissue biopsies. We leverage cutting-edge liquid biopsy technology to improve the accuracy of cancer diagnosis, treatment monitoring, and ultimately, patient survival. Our ultrasensitive tests detect actionable mutations, enabling personalized treatment strategies and improved patient outcomes. We're making a significant impact on the oncology landscape by providing unparalleled sensitivity and specificity in minimal residual disease (MRD) detection. Our tech stack includes Amazon Web Services (AWS), including Elastic Load Balancing and services within their North Virginia and Stockholm regions. We also utilize DNSSEC for enhanced security and leverage the CrUX dataset for performance monitoring. We foster a collaborative engineering culture focused on delivering innovative solutions. We believe in a data-driven approach and invest heavily in research and development to stay ahead of the curve in genomic diagnostics. SAGA Diagnostics is committed to improving precision cancer medicine. We're a fast-growing company with significant funding, attracting international attention. We prioritize teamwork, innovation, and a positive impact on patient care. We offer remote work opportunities and encourage a diverse and inclusive workplace – where every individual is vital to our success and global reach. With a strong series A funding round secured in 2021, SAGA Diagnostics is rapidly expanding its operations and its impact on cancer diagnostics worldwide. We offer a generous benefits package that includes medical, dental, vision, and paid parental leave, alongside equity participation, reflecting our belief in supporting our employees’ well-being and growth.
Natera is a company specializing in genetic testing and diagnostics, harnessing advanced technologies to provide insights into health and disease.
Prenetics is a leading genomics-driven health sciences company focused on revolutionizing health through prevention, early detection, and treatment. With innovative products like CircleDNA, a comprehensive consumer DNA test, and Insighta, a joint venture aimed at early cancer detection, Prenetics is committed to enhancing global health through advanced scientific solutions.
Abbott is engaged in pharmaceuticals and manufacturing healthcare products. It developed the first HIV blood-screening test. Its product portfolio includes Norvir, a treatment for HIV; Synthroid, a synthetic thyroid hormone; Depakote, an anticonvulsant drug; and Humira, a drug for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and more.
Element Biosciences is revolutionizing genetic analysis with its innovative, high-performing DNA sequencing platform. We develop modular solutions that deliver superior data quality, workflow flexibility, and significantly reduced costs, making next-generation sequencing more accessible to researchers worldwide. Our proprietary approach focuses on enhancing the signal-to-noise ratio through breakthroughs in surface chemistry, instrumentation, and biochemistry. We're a fast-growing company with a strong engineering culture built on collaboration and innovation. Our tech stack includes technologies like nginx, Google Tag Manager, and various mobile-optimized features, reflecting our commitment to efficient and user-friendly solutions. We pride ourselves on scientific integrity, collegiality, and a supportive work environment where employees can learn and grow. Our mission is to empower researchers to better understand biology and improve global health. We value honesty, objectivity, and openness in all our interactions, both internally and with our customers. Our commitment to these values has resulted in significant funding, including a recent Series D round, allowing us to continue our rapid expansion and development. We offer a diverse range of roles, including many remote opportunities and positions that contribute to the development of our innovative platform. We encourage collaboration across disciplines and provide ample opportunities for professional development. Our remote-friendly culture, combined with a global presence, allows us to attract and retain top talent from across the globe. Join our team and contribute to the future of genetic analysis. Element Biosciences is a rapidly expanding life sciences company with over 250 employees and significant funding, attracting leading investors in the field. We provide competitive compensation and benefits, including stock options, health insurance, and flexible paid time off, to ensure a rewarding experience for all our team members. We are an equal opportunity employer committed to fostering a diverse and inclusive workplace.
4D Molecular Therapeutics is a clinical-stage biotherapeutics company pioneering the development of targeted genetic medicines. We leverage our proprietary Therapeutic Vector Evolution (TVE) platform, combining directed evolution with a vast library of AAV capsid sequences, to create highly effective and targeted gene therapy products for a wide range of significant diseases. Unlike many gene therapy companies focused on rare diseases, 4DMT is tackling large market opportunities, offering significant potential for impact. Our fully integrated approach extends from research and development to in-house GMP manufacturing, allowing us to move rapidly from concept to clinical trials. We currently have five product candidates in clinical trials and two pre-clinical programs underway, showcasing our ability to innovate and execute. Our tech stack supports our agile and collaborative engineering culture, and includes technologies such as Google Tag Manager, Google Analytics, and various security protocols (SPF, SSL, DNSSEC, HSTS). We're committed to pushing boundaries in gene therapy, and our initial clinical data validates the power of our platform. 4DMT offers a dynamic and rewarding work environment. We're a growing company (101-250 employees) with a robust intellectual property portfolio and a strong financial foundation, evidenced by our significant funding rounds. We offer remote work opportunities for many roles, providing flexibility and access to talent across the United States and beyond. Our culture values collaboration, innovation, and a commitment to advancing gene therapy to improve patient lives. We are actively expanding our pipeline and exploring additional indications and modalities within genetic medicine, offering exciting opportunities for growth and advancement within the company. Our continued success in attracting top talent and securing substantial funding reinforces our position as a leader in the gene therapy field.